Hostname: page-component-6766d58669-76mfw Total loading time: 0 Render date: 2026-05-19T12:38:34.036Z Has data issue: false hasContentIssue false
  • English
  • Français

Does systemic clarithromycin therapy have an inhibitory effect on tympanosclerosis? An experimental animal study

Published online by Cambridge University Press:  26 January 2015

G Genc ,
M Koyuncu ,
G Kutlar ,
T Guvenc ,
A Gacar ,
A Aksoy ,
S Arslan  and
S C Kurnaz
G Genc*
Affiliation:
Department of Otolaryngology, School of Medicine, Ondokuz Mayis University, Samsun, Turkey
M Koyuncu
Affiliation:
Department of Otolaryngology, School of Medicine, Ondokuz Mayis University, Samsun, Turkey
G Kutlar
Affiliation:
Department of Otolaryngology, School of Medicine, Ondokuz Mayis University, Samsun, Turkey
T Guvenc
Affiliation:
Department of Pathology, Faculty of Veterinary Medicine, Ondokuz Mayis University, Samsun, Turkey
A Gacar
Affiliation:
Department of Pathology, Faculty of Veterinary Medicine, Ondokuz Mayis University, Samsun, Turkey
A Aksoy
Affiliation:
Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Ondokuz Mayis University, Samsun, Turkey
S Arslan
Affiliation:
Department of Biometry, Faculty of Veterinary Medicine, Ondokuz Mayis University, Samsun, Turkey
S C Kurnaz
Affiliation:
Department of Otolaryngology, School of Medicine, Ondokuz Mayis University, Samsun, Turkey
*
Address for correspondence: Dr Gunes Genc, Department of Otolaryngology, School of Medicine, Ondokuz Mayis University, 55139 Kurupelit, Samsun, Turkey E-mail: gencgunes@gmail.com
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

To demonstrate the inhibitory effects of clarithromycin on in vitro tympanosclerosis.

Method:

Twenty-eight rats were divided into three groups: a clarithromycin group, a non-clarithromycin group and a negative control group. Those in the first two groups were injected with Streptococcus pneumoniae following a myringotomy, and tympanosclerosis was experimentally induced. Oral clarithromycin therapy was administered in the clarithromycin group. The other groups received no medical treatment.

Results:

All eardrums in the clarithromycin and non-clarithromycin groups developed myringosclerosis, but there was only one eardrum, in the clarithromycin group, with very severe myringosclerosis. In the clarithromycin group, 11 ears showed no inflammation and there were no ears with severe inflammation. In the non-clarithromycin group, there were 11 ears with severe inflammation. The mean eardrum thickness in the clarithromycin group was 20.93 µm and in the non-clarithromycin group it was 42.71 µm.

Conclusion:

Acute otitis media and myringotomies induced tympanosclerosis, but clarithromycin reduced the severity of tympanosclerosis.

Keywords

TympanosclerosisClarithromycinMiddle EarOtitis Media

Information

Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 129 , Issue 2 , February 2015 , pp. 136 - 141
Copyright
Copyright © JLO (1984) Limited 2015 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

1Sorensen, H, True, O. Histology of tympanosclerosis. Acta Otolaryngol 1972;73:18–26Google Scholar
2Ferlito, A. Histopathogenesis of tympanosclerosis. J Laryngol Otol 1979;93:25–37Google Scholar
3da Costa, SS, Paparella, MM, Schachern, PA, Yoon, TH, Kimberley, BP. Temporal bone histopathology in chronically infected ears with intact and perforated tympanic membranes. Laryngoscope 1992;102:1229–36Google Scholar
4Tos, M, Bonding, P, Poulsen, G. Tympanosclerosis of the drum in secretory otitis after insertion of grommets. A prospective, comparative study. J Laryngol Otol 1983;97:489–96Google Scholar
5Forseni Flodin, M, Hultcrantz, M. Possible inflammatory mediators in tympanosclerosis development. Int J Pediatr Otorhinolaryngol 2002;63:149–54Google Scholar
6Mattsson, C, Magnuson, K, Hellstrom, S. Myringosclerosis caused by increased oxygen concentration in traumatized tympanic membranes. Experimental study. Ann Otol Rhinol Laryngol 1995;104:625–32Google Scholar
7Mattsson, C, Marklund, SL, Hellstrom, S. Application of oxygen free radical scavengers to diminish the occurrence of myringosclerosis. Ann Otol Rhinol Laryngol 1997;106:513–18Google Scholar
8Spratley, JE, Hellström, SO, Mattsson, CK, Pais-Clemente, M. Topical ascorbic acid reduces myringosclerosis in perforated tympanic membranes. A study in the rat. Ann Otol Rhinol Laryngol 2001;110:585–91Google Scholar
9Kaptan, ZK, Emir, H, Gocmen, H, Uzunkulaoglu, H, Karakas, A, Senes, M et al. Ginkgo biloba, a free oxygen radical scavenger, affects inflammatory mediators to diminish the occurrence of experimental myringosclerosis. Acta Otolaryngol 2009;129:826–31Google Scholar
10Aslan, H, Basoglu, MS, Senturk, B, Ozbay, C, Katilmis, H, Ozturkcan, S. Serum matrix metalloproteinases and tympanosclerosis. J Laryngol Otol 2011;125:142–6Google Scholar
11Hardy, RD, Rios, AM, Chavez-Bueno, S, Jafri, HS, Hatfield, J, Rogers, BB et al. Antimicrobial and immunologic activities of clarithromycin in a murine model of Mycoplasma pneumoniae-induced pneumonia. Antimicrob Agents Chemother 2003;47:1614–20Google Scholar
12Nakajima, T, Hishikari, K, Ogawa, M, Watanabe, R, Suzuki, J, Nagashima, A et al. Clarithromycin attenuates myocardial ischemia-reperfusion injury. Expert Opin Ther Targets 2010;14:881–93Google Scholar
13Ozcan, C, Gorur, K, Cinel, L, Talas, DU, Unal, M, Cinel, I. The inhibitory effect of topical N-acetylcysteine application on myringosclerosis in perforated rat tympanic membrane. Int J Pediatr Otorhinolaryngol 2002;63:179–84Google Scholar
14Maw, AR, Bawden, R. Tympanic membrane atrophy, scarring, atelectasis and attic retraction in persistent, untreated otitis media with effusion and following ventilation tube insertion. Int J Pediatr Otorhinolaryngol 1994;30:189–204Google Scholar
15Daly, KA, Hunter, LL, Lindgren, BR, Margolis, R, Giebink, GS. Chronic otitis media with effusion sequelae in children treated with tubes. Arch Otolaryngol Head Neck Surg 2003;129:517–22Google Scholar
16Johnston, LC, Feldman, HM, Paradise, JL, Bernard, BS, Colborn, DK, Casselbrant, ML et al. Tympanic membrane abnormalities and hearing levels at the ages of 5 and 6 years in relation to persistent otitis media and tympanostomy tube insertion in the first 3 years of life: a prospective study incorporating a randomized clinical trial. Pediatrics 2004;114:e58–67Google Scholar
17Kay, DJ, Nelson, M, Rosenfeld, RM. Meta-analysis of tympanostomy tube sequelae. Otolaryngol Head Neck Surg 2001;124:374–80Google Scholar
18Pereira, MB, Pereira, DR, Costa, SS. Tympanostomy tube sequelae in children with otitis media with effusion: a three-year follow-up study. Braz J Otorhinolaryngol 2005;71:415–20Google Scholar
19Pappas, DE, Owen Hendley, J. Otitis media. A scholarly review of the evidence. Minerva Pediatr 2003;55:407–14Google Scholar
20Lieberthal, AS, Carroll, AE, Chonmaitree, T, Ganiats, TG, Hoberman, A, Jackson, MA et al. The diagnosis and management of acute otitis media. Pediatrics 2013;131:e964–99Google Scholar
21Vergison, A, Dagan, R, Arguedas, A, Bonhoeffer, J, Cohen, R, Dhooge, I et al. Otitis media and its consequences: beyond the earache. Lancet 2010;10:195–203Google Scholar
22Tähtinen, PA, Laine, MK, Huovinen, P, Jalava, J, Ruuskanen, O, Ruohola, A. A placebo-controlled trial of antimicrobial treatment for acute otitis media. N Engl J Med 2011;364:116–26Google Scholar
23Ozdemir, OM, Ergin, H, Yenisey, C, Turk, NS, Simsek, NG. Protective effects of clarithromycin in rats with hypoxia/reoxygenation-induced intestinal injury. J Pediatr Surg 2010;45:2169–74Google Scholar
24Ozcan, I, Selcuk, A, Ozcan, KM, Akdogan, O, Giray, SG, Dere, H et al. The effect of topical doxycycline in the prevention of experimental tympanosclerosis. Laryngoscope 2008;118:1051–6Google Scholar
25Peric, A, Vojvodic, D, Baletic, N, Peric, A, Miljanovic, O. Influence of allergy on the immunomodulatory and clinical effects of long-term low-dose macrolide treatment of nasal polyposis. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2010;154:327–33Google Scholar
26Hashiba, M, Baba, S. Efficacy of long-term administration of clarithromycin in the treatment of intractable chronic sinusitis. Acta Otolaryngol 1996;525:73–8Google Scholar